Barclays Lowers Bruker (NASDAQ:BRKR) Price Target to $45.00

Bruker (NASDAQ:BRKR) had its target price reduced by Barclays from $50.00 to $45.00 in a report released on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. Barclays‘s target price would indicate a potential upside of 12.78% from the company’s current price.

Several other equities research analysts have also recently issued reports on the company. TD Cowen lowered their price objective on Bruker from $53.00 to $43.00 and set a “hold” rating on the stock in a report on Friday, February 13th. Citigroup lowered their price objective on Bruker from $53.00 to $40.00 and set a “neutral” rating on the stock in a report on Friday, February 13th. JPMorgan Chase & Co. lifted their price objective on Bruker from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Guggenheim lowered their price objective on Bruker from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Finally, Jefferies Financial Group set a $50.00 price objective on Bruker in a report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $49.38.

Bruker Price Performance

BRKR stock traded up $0.85 during trading on Tuesday, hitting $39.90. The stock had a trading volume of 1,954,948 shares, compared to its average volume of 2,337,056. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87. Bruker has a twelve month low of $28.53 and a twelve month high of $56.22. The stock has a market capitalization of $6.07 billion, a P/E ratio of -266.00, a PEG ratio of 2.25 and a beta of 1.20. The company’s 50-day moving average price is $37.63 and its two-hundred day moving average price is $41.65.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.06). Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The firm had revenue of $977.20 million during the quarter, compared to analyst estimates of $964.61 million. During the same quarter in the previous year, the firm posted $0.76 earnings per share. The company’s quarterly revenue was down .2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts predict that Bruker will post 2.69 EPS for the current fiscal year.

Insiders Place Their Bets

In other Bruker news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $35.44, for a total value of $70,880.00. Following the transaction, the vice president directly owned 128,443 shares of the company’s stock, valued at $4,552,019.92. This trade represents a 1.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 27.30% of the stock is owned by company insiders.

Institutional Trading of Bruker

Institutional investors have recently made changes to their positions in the company. Sector Gamma AS increased its holdings in Bruker by 28.0% in the 3rd quarter. Sector Gamma AS now owns 250,909 shares of the medical research company’s stock valued at $8,152,000 after purchasing an additional 54,939 shares during the last quarter. Becker Capital Management Inc. increased its holdings in Bruker by 606.8% in the 3rd quarter. Becker Capital Management Inc. now owns 301,155 shares of the medical research company’s stock valued at $9,800,000 after purchasing an additional 258,545 shares during the last quarter. DNB Asset Management AS increased its holdings in Bruker by 40.5% in the 3rd quarter. DNB Asset Management AS now owns 143,257 shares of the medical research company’s stock valued at $4,654,000 after purchasing an additional 41,289 shares during the last quarter. Aquatic Capital Management LLC increased its holdings in Bruker by 120.3% in the 3rd quarter. Aquatic Capital Management LLC now owns 349,596 shares of the medical research company’s stock valued at $11,358,000 after purchasing an additional 190,883 shares during the last quarter. Finally, M&G PLC increased its holdings in Bruker by 233.0% in the 3rd quarter. M&G PLC now owns 1,096,226 shares of the medical research company’s stock valued at $35,079,000 after purchasing an additional 766,992 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.